Evidence map›Paper›PMID 41319397›Full record

Trial reportVaccine2026

Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination.

Sharon E Frey, Lindsey R Baden, Hana M El Sahly, Richard T Davey, Paulina A Rebolledo, David J Diemert, Susan J Little, C Buddy Creech, Zacharoula Oikonomopoulou, Amy C Sherman and 13 more

Abstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sharon E FreySaint Louis University Center for Vaccine Development, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA.
Lindsey R BadenBrigham and Women's Hospital, Division of Infectious Diseases, Harvard Medical School, Boston, MA, USA.
Hana M El SahlyBaylor College of Medicine, Departments of Molecular Virology & Microbiology and Medicine, Houston, TX, USA.
Richard T DaveyNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Paulina A RebolledoHope Clinic, Emory Vaccine Center, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
David J DiemertGeorge Washington Vaccine Research Center, Department of Medicine, George Washington University, Washington, DC, USA.
Susan J LittleDivision of Infectious Diseases & Global Public Health, University of California San Diego, San Diego, CA, USA.
C Buddy CreechVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.
Zacharoula OikonomopoulouSaint Louis University Center for Vaccine Development, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA.
Amy C ShermanBrigham and Women's Hospital, Division of Infectious Diseases, Harvard Medical School, Boston, MA, USA.
Jennifer A WhitakerBaylor College of Medicine, Departments of Molecular Virology & Microbiology and Medicine, Houston, TX, USA.
Nadine G RouphaelHope Clinic, Emory Vaccine Center, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Aimee DesrosiersGeorge Washington Vaccine Research Center, Department of Medicine, George Washington University, Washington, DC, USA.
Thomas C S MartinDivision of Infectious Diseases & Global Public Health, University of California San Diego, San Diego, CA, USA.
Stephanie L RolsmaVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA.
Bernard HoetBavarian Nordic Belgium, Brussels, Belgium.
Amy WatanabeThe Emmes Company, LLC, Rockville, MD, USA.
Anna JaunarajsThe Emmes Company, LLC, Rockville, MD, USA.
Bernard MossNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kay M TomashekNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Andrea LernerNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
John H BeigelNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
DMID 22-0020 Study Group

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Statistical Data Coordinating Center: Monkeypox Clinical Research Support75N93021C00012 · NIAID · THE EMMES COMPANY, LLC · PI EWELL, MARIAN · 2021 to 2025
$150.3M
NCI NIH HHS 75N91019D00024NIAID NIH HHS 75N93021C00012
6 · The paper itself

Abstract

introductionModified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is being used to mitigate disease in the current global mpox outbreak, but a global vaccine shortage may limit large scale vaccination.

methodsParticipants were randomized 1:1:1 to receive two doses of MVA-BN administered 28 days apart: intradermal (ID) 2 × 10

resultsDay 43 non-inferiority by PRNT GMT was established for the 2 × 10

conclusionThe 2 × 10 CLINICALTRIALS: govNCT05512949.

Indexed as

Immunogenicity, VaccineSmallpox VaccineAdolescentAdultAntibodies, NeutralizingAntibodies, ViralFemaleHumansImmunity, HumoralImmunization ScheduleInjections, IntradermalInjections, SubcutaneousMaleMiddle AgedVaccinationVaccinia virusAntibodies, NeutralizingAntibodies, ViralSmallpox VaccineCladeDose-de-escalationIntradermalMpoxMVA-BNVaccinia

Identifiers

PMID41319397
PMCPMC13105150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.